menu search

Astrazeneca seeks emergency use authorisation for covid-19 antibody drug in us

AstraZeneca PLC has requested authorisation in the US for emergency use of its new antibody combination...

October 5, 2021, 4:31 am

Astrazeneca seeks emergency use authorisation for covid-19 antibody drug in us

AstraZeneca PLC has requested authorisation in the US for emergency use of its new antibody combination...

October 5, 2021, 4:31 am

Astrazeneca seeks emergency use authorisation for covid-19 antibody drug in us

AstraZeneca PLC has requested authorisation in the US for emergency use of its new antibody combination...

October 5, 2021, 4:31 am

Astrazeneca seeks emergency use authorisation for covid-19 antibody drug in us

AstraZeneca PLC has requested authorisation in the US for emergency use of its new antibody combination...

October 5, 2021, 4:31 am

Astrazeneca seeks emergency use authorisation for covid-19 antibody drug in us

AstraZeneca PLC has requested authorisation in the US for emergency use of its new antibody combination...

October 5, 2021, 4:31 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am


Search within

Pages Search Results: